175 related articles for article (PubMed ID: 34637107)
41. Methotrexate Polyglutamate Concentrations as a Possible Predictive Marker for Effectiveness of Methotrexate Therapy in Patients with Sarcoidosis: A Pilot Study.
Janssen Bonás M; Sundaresan J; Keijsers RGM; Struys EA; Peters BJM; Kahlmann V; Wijsenbeek MS; de Rotte MCFJ; Grutters JC; Veltkamp M
Lung; 2023 Dec; 201(6):617-624. PubMed ID: 37973683
[TBL] [Abstract][Full Text] [Related]
42. Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis.
Dervieux T; Weinblatt ME; Kivitz A; Kremer JM
Ann Rheum Dis; 2013 Jun; 72(6):908-10. PubMed ID: 23161901
[TBL] [Abstract][Full Text] [Related]
43. Time course of methotrexate polyglutamate formation and degradation in the pre-B-leukaemia cell line Nalm6 and in lymphoblasts from children with leukaemia.
Buchholz B; Frei E; Eisenbarth J; Weigand M; Ludwig R
Eur J Cancer; 1996 Nov; 32A(12):2101-7. PubMed ID: 9014752
[TBL] [Abstract][Full Text] [Related]
44. Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach.
Odoul F; Le Guellec C; Lamagnère JP; Breilh D; Saux MC; Paintaud G; Autret-Leca E
Fundam Clin Pharmacol; 1999; 13(5):595-604. PubMed ID: 10520733
[TBL] [Abstract][Full Text] [Related]
45. Evidence for negative feedback of extracellular methotrexate on blasts of acute lymphoblastic leukemia in vitro.
Hum MC; Smith AK; Lark RH; Winick NJ; Kamen BA
Pharmacotherapy; 1997; 17(6):1260-6. PubMed ID: 9399609
[TBL] [Abstract][Full Text] [Related]
46. Effects of sodium in hydration solution on plasma methotrexate concentrations following high-dose methotrexate in children with acute lymphoblastic leukemia.
Kinoshita A; Kurosawa Y; Kondoh K; Suzuki T; Manabe A; Inukai T; Sugita K; Nakazawa S
Cancer Chemother Pharmacol; 2003 Mar; 51(3):256-60. PubMed ID: 12655445
[TBL] [Abstract][Full Text] [Related]
47. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology.
Schmiegelow K; Schrøder H; Gustafsson G; Kristinsson J; Glomstein A; Salmi T; Wranne L
J Clin Oncol; 1995 Feb; 13(2):345-51. PubMed ID: 7531219
[TBL] [Abstract][Full Text] [Related]
48. Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia.
French D; Yang W; Cheng C; Raimondi SC; Mullighan CG; Downing JR; Evans WE; Pui CH; Relling MV
Blood; 2009 May; 113(19):4512-20. PubMed ID: 19066393
[TBL] [Abstract][Full Text] [Related]
49. Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia.
Maiguma T; Hayashi Y; Ueshima S; Kaji H; Egawa T; Chayama K; Morishima T; Kitamura Y; Sendo T; Gomita Y; Teshima D
Int J Clin Pharmacol Ther; 2008 Nov; 46(11):584-90. PubMed ID: 19000557
[TBL] [Abstract][Full Text] [Related]
50. Effect of Body Fat on Population Pharmacokinetics of High-Dose Methotrexate in Pediatric Patients With Acute Lymphoblastic Leukemia.
Orgel E; Nabais T; Douglas C; Mittelman SD; Neely M
J Clin Pharmacol; 2021 Jun; 61(6):755-762. PubMed ID: 33314168
[TBL] [Abstract][Full Text] [Related]
51. Assessment of renal function during high-dose methotrexate treatment in children with acute lymphoblastic leukemia.
Ylinen E; Jahnukainen K; Saarinen-Pihkala UM; Jahnukainen T
Pediatr Blood Cancer; 2014 Dec; 61(12):2199-202. PubMed ID: 25174822
[TBL] [Abstract][Full Text] [Related]
52. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.
Wolfrom C; Hepp R; Hartmann R; Breithaupt H; Henze G
Eur J Clin Pharmacol; 1990; 39(4):377-83. PubMed ID: 2076721
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study.
Balis FM; Holcenberg JS; Poplack DG; Ge J; Sather HN; Murphy RF; Ames MM; Waskerwitz MJ; Tubergen DG; Zimm S; Gilchrist GS; Bleyer WA
Blood; 1998 Nov; 92(10):3569-77. PubMed ID: 9808549
[TBL] [Abstract][Full Text] [Related]
55. Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia.
Liu Y; Yin Y; Sheng Q; Lu X; Wang F; Lin Z; Tian H; Xu A; Zhang J
PLoS One; 2014; 9(1):e82681. PubMed ID: 24404132
[TBL] [Abstract][Full Text] [Related]
56. Methotrexate Polyglutamates Analysis by Chromatography Methods in Biological Matrices: A Review.
Zhang Y; Sun L; Zhao L; Wang X; Zhao Z; Mei S
Anal Sci; 2021 Dec; 37(12):1655-1664. PubMed ID: 34024867
[TBL] [Abstract][Full Text] [Related]
57. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.
Relling MV; Hancock ML; Boyett JM; Pui CH; Evans WE
Blood; 1999 May; 93(9):2817-23. PubMed ID: 10216075
[TBL] [Abstract][Full Text] [Related]
58. Methotrexate Polyglutamation in a Myasthenia Gravis Clinical Trial.
Pasnoor M; Heim AJ; Herbelin L; Statland J; Dimachkie MM; Becker M; Barohn RJ;
Kans J Med; 2020; 13(Suppl 2):10-13. PubMed ID: 32256969
[TBL] [Abstract][Full Text] [Related]
59. Influence of plasma methotrexate level and MTHFR genotype in Korean paediatric patients with acute lymphoblastic leukaemia.
Chae H; Kim M; Choi SH; Kim SK; Lee JW; Chung NG; Cho B; Kim Y
J Chemother; 2020 Sep; 32(5):251-259. PubMed ID: 32431230
[TBL] [Abstract][Full Text] [Related]
60. Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate.
Rask C; Albertioni F; Schrøder H; Peterson C
Pediatr Hematol Oncol; 1996; 13(4):359-67. PubMed ID: 8837142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
